2068119-11-7

S18-000003 (30-100 mg/kg; p.o.) inhibits IL-17 production in the skin of IL-23-treated mice in a dose-dependent manner^[1].
S18-000003 (0.1-8%; 100mL; topically administration once daily for 14 days) ameliorates psoriasis-like lesions in TPA-induced K14.Stat3C transgenic mice, and has little impact on the thymus^[2].
S18-000003 (0.5 mg/kg; i.v.) exhibits the half-life (3.2 h), AUC (1930 ng h/mL), CL_tot (4.33 mL/min/kg) and Vd_ss in rats^[1].
S18-000003 (1 mg/kg; p.o.) exhibits the oral bioavailability (54.5%), C_max (185 ng/mL), AUC (2110 ng h/mL) and T_max (4 h) in rats^[1].